Skip to content
My WebMD Sign In, Sign Up

Osteoporosis Health Center

Font Size
A
A
A

Drugs Cut Bone Loss of Hormone Therapy

Bisphosphonates Counter Side Effect of Treatment for Breast Cancer
By
WebMD Health News

Bone Drug and Breast Cancer

Dec. 14, 2007 (San Antonio) -- The bone-building drugs known as bisphosphonates can offset a side effect of hormone therapy for breast cancer -- significant bone loss that can lead to fractures, three new studies suggest.

Researchers from the Austrian Breast and Colorectal Cancer Study Group report that the drug Zometa helped to build bone in premenopausal women taking Arimidex for breast cancer. Arimidex is a hormone therapy used in breast cancer patients that helps lower estrogen levels.

U.S. researchers found that postmenopausal women taking another hormone therapy used in breast cancer patients -- Femara -- were less likely to suffer bone loss if they received concomitant treatment with Zometa.

And British researchers say the biphosphonate Actonel helped to preserve bone in women taking Arimidex.

(Are you concerned about bone loss during your breast cancer treatment? Talk about it on WebMD's Breast Cancer: Friend to Friend board.)  

Hormone Therapy Causes Bone Loss

About 70% of women with breast cancer have tumors that are fueled by estrogen, making hormone therapy a cornerstone of regimens to prevent recurrences and improve survival.

Doctors have used the hormone drug tamoxifen, which deprives breast cancer cells of the estrogen they need to grow, to slow tumor growth in these women for years.

More recently, they started using the more potent hormone treatments called aromatase inhibitors to shrink tumors. The drugs block an enzyme the body uses to make estrogen, thereby slashing the body's production of estrogen altogether.

These drugs can be lifesaving, but suppressed estrogen levels increase bone turnover and accelerate bone loss, says Adam Brufsky, MD, of the University of Pittsburgh. He led the American study.

Bisphosphonates increase bone formation and decreasing bone turnover, he explains.

"Aromatase inhibitors cause bone loss and these drugs can ameliorate that loss," says Eric Winer, MD, a breast cancer specialist at the Dana-Farber Cancer Institute in Boston who wasn't involved with the work.

Zometa is approved for preventing fractures in patients with advanced bone cancer. Actonel is commonly used to prevent or treat osteoporosis in postmenopausal women.

The research was presented here at the annual San Antonio Breast Cancer Symposium.

Zometa Helps Build Bone

The Australian study involved over 400 premenopausal women with early-stage breast cancer; they received hormone therapy to prevent recurrence of breast cancer. The women were being treated by tamoxifen and Zoladex, or Arimidex and Zoladex.

In addition, half the women received treatment with the bone-building drug Zometa. The medication was given once every six months for three years.

Bone density measurements of the spine were taken at the beginning of the study and two years after treatment ended.

Results show that women who did not receive Zometa during hormonal therapy lost 6.3% of their bone mineral density.

In contrast, bone mineral density increased by 4.4% in women who took Zometa, says researcher Michael Gnant, MD, of the University of Vienna in Austria.

Today on WebMD

thumbnail_man_feeding_woman_strawberry
Slideshow
Managing OAB
Article
 
Vitamin D
Slideshow
osteoporosis overview
Slideshow
 
Lactose Intolerance
Article
Woman holding plate of brocolli
Article
 
Dairy products
Tool
Superfood for Bones
Slideshow
 
Endocrinologists in Your Area
Screening Tests for Women
Slideshow
exercise endometrial cancer
Article
 
hand holding medicine
Article
Working Out With Osteoporosis
Video